{"filing":{"accession_number":"0001575872-26-000489","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-07-09","report_date":null,"primary_document":"rdy0917_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000489/rdy0917_6k.htm"},"events":[{"id":16781,"run_id":15009,"accession_number":"0001575872-26-000489","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Dr. Reddy's discloses that certain batches of semaglutide (a key metabolic therapy product) were found out-of-specification due to an active pharmaceutical ingredient (API) issue, requiring investigation and causing commercial supply delays. While no patient safety impact is claimed, the disclosure of a product quality issue affecting a major commercial product with delayed supplies is a material operational event affecting the company's ability to fulfill market demand. This does not fit the specific categories of material_impairment, restatement, or cybersecurity_incident, but represents a material operational/quality disruption requiring disclosure under SEBI Regulation 30.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-09","form":"6-K","submitted_at":null,"items":[{"id":14979,"accession_number":"0001575872-26-000489","item_number":"EX-99.1","item_title":"rdy0917_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Dr. Reddy's discloses that certain batches of semaglutide (a key metabolic therapy product) were found out-of-specification due to an active pharmaceutical ingredient (API) issue, requiring investigation and causing commercial supply delays. While no patient safety impact is claimed, the disclosure of a product quality issue affecting a major commercial product with delayed supplies is a material operational event affecting the company's ability to fulfill market demand. This does not fit the specific categories of material_impairment, restatement, or cybersecurity_incident, but represents a material operational/quality disruption requiring disclosure under SEBI Regulation 30.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:27:52.357880+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14979,"accession_number":"0001575872-26-000489","item_number":"EX-99.1","item_title":"rdy0917_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Dr. Reddy's discloses that certain batches of semaglutide (a key metabolic therapy product) were found out-of-specification due to an active pharmaceutical ingredient (API) issue, requiring investigation and causing commercial supply delays. While no patient safety impact is claimed, the disclosure of a product quality issue affecting a major commercial product with delayed supplies is a material operational event affecting the company's ability to fulfill market demand. This does not fit the specific categories of material_impairment, restatement, or cybersecurity_incident, but represents a material operational/quality disruption requiring disclosure under SEBI Regulation 30.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:27:52.357880+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-09"}]}